Chunsheng Kang
Tianjin Medical University General Hospital
285 Papers
817 Citations
Chunsheng Kang is an academic researcher from Tianjin Medical University General Hospital. The author has contributed to research in topics: Glioma & Biology. The author has an hindex of 64, co-authored 265 publications. Previous affiliations of Chunsheng Kang include Nanjing Medical University & Tianjin University.
Chat about Author
Papers
Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo.
Jing Zhang,Qingyu Zhang,Yan-chao Fu,Tao Wang,Jie Zhang,Peng Xu,Xuan Zhou,Peiyu Pu,Chunsheng Kang +8 more
TL;DR: In this article, immunohistochemical expression of phosphorylated Akt (p-Akt) and COX-2 in 45 gastric adenocarcinomas with different tumor grades was examined.
20
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Fei Tong,Jixing Zhao,Zijing Fang,Xiaoteng Cui,Dong-yuan Su,Xing Liu,Junhu Zhou,Guangbin Wang,Zhijun Qiu,Shi-zhong Liu,Jun-qi Fu,Chunsheng Kang,Jiacheng Wang,Qixue Wang +13 more
TL;DR: In this article , a small molecule, EPIC-1027, was used to stabilize EGFRvIII in glioblastoma (GBM) using CRISPR-Cas9 library screening.
20
Preparation and Evaluation of 5-FU/PLGA/Gene Nanoparticles
TL;DR: It was proved that plasmids on the surface of nanoparticles could transfect gliomas cells, verified by a decline in the expression level of EGFR protein by the glioma cells, and provides another therapeutic pathway for cancer and needs further research.
20
EGFR-vIII downregulated H2AZK4/7AC though the PI3K/AKT-HDAC2 axis to regulate cell cycle progression
Hongyu Zhao,Yunfei Wang,Chao Yang,Junhu Zhou,Lin Wang,Kaikai Yi,Yansheng Li,Qixue Wang,Jin Shi,Chunsheng Kang,Liang Zeng +10 more
TL;DR: FK228 could enhance anti-tumour activity by upregulating expression of the tumour suppressor USP11 in GBM cells by downregulating H2AZK4/7AC and H3K27AC through the PI3K/AKT-HDAC1/2 axis and is an effective and promising treatment for GBM with EGFR-vIII mutation.
EGFR/EGFRvIII remodels the cytoskeleton via epigenetic silencing of AJAP1 in glioma cells.
Chao Yang,Yansheng Li,Qixue Wang,Kai Huang,Jianwei Wei,Yunfei Wang,Junhu Zhou,Kaikai Yi,Kailiang Zhang,Bingcong Zhou,Cong Liu,Liang Zeng,Chunsheng Kang +12 more
TL;DR: The data suggest that activation of the EGFR signal transduction pathway genetically silences anti-oncogenes to enhance GBM malignancy and MK2206 might be a promising therapeutic for EGFR/EGFRvIII-positive GBMs.
18